Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Immune checkpoint blockade upfront in older AML and HR-MDS

Amer Zeidan • 10 Dec 2019
ASH 2019
Acute Myeloid Leukemia Leukemia Myelodysplastic Syndromes Antibodies Azacitidine Checkpoint inhibitors Durvalumab

Amer Zeidan, MBBS, MHS, Yale University and Yale Cancer Center, New Haven, CT, discusses the first large randomized trial (NCT02775903) of azacitidine with or without immune checkpoint blockade in older unfit acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (MDS). While the study did not reach its primary endpoint, Dr Zeidan reveals the important insights that can be taken away. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Amer Zeidan

1:52
Advances in LR-MDS and HR-MDS in 2023 and beyond
Amer Zeidan • 9 Dec 2023
2:14
Trial updates for luspatercept in LR-MDS: COMMANDS, MEDALIST and ELEMENTS-MDS
Amer Zeidan • 9 Dec 2023
1:45
Real-world data: oral decitabine plus cedazuridine versus IV/SC hypomethylating agents
Amer Zeidan • 9 Dec 2023
2:21
STIMULUS-MDS1: sabatolimab + HMAs in untreated HR-MDS
Amer Zeidan • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals